Published in Carbohydr Res on January 01, 1998
Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans. Cell (2008) 2.71
A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell (2003) 2.59
The capsule of the fungal pathogen Cryptococcus neoformans. Adv Appl Microbiol (2009) 1.97
A eukaryotic capsular polysaccharide is synthesized intracellularly and secreted via exocytosis. Mol Biol Cell (2006) 1.88
Functional cloning and characterization of a UDP- glucuronic acid decarboxylase: the pathogenic fungus Cryptococcus neoformans elucidates UDP-xylose synthesis. Proc Natl Acad Sci U S A (2001) 1.80
Cryptococcus neoformans Galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus Galactomannan. J Clin Microbiol (2005) 1.50
Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot Cell (2007) 1.45
How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol (2009) 1.43
Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence. Mol Microbiol (2007) 1.38
Eukaryotic UDP-galactopyranose mutase (GLF gene) in microbial and metazoal pathogens. Eukaryot Cell (2005) 1.36
Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med (2014) 1.18
Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol (2007) 1.17
Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides. J Biol Chem (2008) 1.14
Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan. Eukaryot Cell (2008) 1.13
The structure of Cryptococcus neoformans galactoxylomannan contains beta-D-glucuronic acid. Carbohydr Res (2009) 1.13
Identification of a bifunctional UDP-4-keto-pentose/UDP-xylose synthase in the plant pathogenic bacterium Ralstonia solanacearum strain GMI1000, a distinct member of the 4,6-dehydratase and decarboxylase family. J Biol Chem (2010) 1.05
The pathogenic fungus Cryptococcus neoformans expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule synthesis. Eukaryot Cell (2007) 1.05
Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol (2011) 1.01
Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryot Cell (2010) 0.98
Emerging themes in cryptococcal capsule synthesis. Curr Opin Struct Biol (2011) 0.96
Involvement of glycoreceptors in galactoxylomannan-induced T cell death. J Immunol (2009) 0.96
Biosynthesis of galactofuranose in kinetoplastids: novel therapeutic targets for treating leishmaniasis and chagas' disease. Enzyme Res (2011) 0.94
Biosynthesis of a new UDP-sugar, UDP-2-acetamido-2-deoxyxylose, in the human pathogen Bacillus cereus subspecies cytotoxis NVH 391-98. J Biol Chem (2010) 0.92
Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage. PLoS One (2010) 0.89
Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast Cryptococcus neoformans. J Biol Chem (2013) 0.89
A novel xylosylphosphotransferase activity discovered in Cryptococcus neoformans. J Biol Chem (2009) 0.88
Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage. J Immunol (2009) 0.88
Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan. Infect Immun (2004) 0.85
Capsular polysaccharides from Cryptococcus neoformans modulate production of neutrophil extracellular traps (NETs) by human neutrophils. Sci Rep (2015) 0.85
A xylosylphosphotransferase of Cryptococcus neoformans acts in protein O-glycan synthesis. J Biol Chem (2011) 0.84
Glucuronoxylomannan, galactoxylomannan, and mannoprotein occupy spatially separate and discrete regions in the capsule of Cryptococcus neoformans. Virulence (2010) 0.84
Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis. Vaccine (2011) 0.83
A unique alpha-1,3 mannosyltransferase of the pathogenic fungus Cryptococcus neoformans. J Bacteriol (1999) 0.82
A Paracoccidioides brasiliensis glycan shares serologic and functional properties with cryptococcal glucuronoxylomannan. Fungal Genet Biol (2012) 0.81
Synthesis of cell envelope glycoproteins of Cryptococcus laurentii. Carbohydr Res (2007) 0.80
Cryptococcus neoformans dual GDP-mannose transporters and their role in biology and virulence. Eukaryot Cell (2014) 0.80
Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly. Eukaryot Cell (2014) 0.79
Production of extracellular polysaccharides by CAP mutants of Cryptococcus neoformans. Eukaryot Cell (2009) 0.78
The role of the cell wall in fungal pathogenesis. Microb Biotechnol (2008) 0.76
Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med (2001) 6.27
Interaction site of Escherichia coli cyclic AMP receptor protein on DNA of galactose operon promoters. Proc Natl Acad Sci U S A (1979) 3.83
Economic evaluation of robot-assisted hysterectomy: a cost-minimisation analysis. BJOG (2014) 3.25
Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol Immunol (1980) 2.98
Cytotoxic activities of gut mucosal lymphoid cells in guinea pigs. J Immunol (1978) 2.70
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun (1988) 2.11
Cell-wall glucans of Cryptococcus neoformans Cap 67. Carbohydr Res (1990) 2.08
Measurement of the rate of nu(e) + d --> p + p + e(-) interactions produced by (8)B solar neutrinos at the Sudbury Neutrino Observatory. Phys Rev Lett (2001) 1.88
Fractionation and characterization of galactoxylomannan from Cryptococcus neoformans. Carbohydr Res (1984) 1.79
Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect Immun (1980) 1.65
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans. Diagn Immunol (1984) 1.57
Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect Immun (1989) 1.55
Embryology of the acetabular labral-chondral complex. J Bone Joint Surg Br (2008) 1.52
Localization of mannoprotein in Cryptococcus neoformans. J Bacteriol (1989) 1.52
Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun (1997) 1.52
Structural determination of oligosaccharides derived from lipooligosaccharide of Neisseria gonorrhoeae F62 by chemical, enzymatic, and two-dimensional NMR methods. Biochemistry (1991) 1.49
Induction of TNF-alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein. J Immunol (1997) 1.43
A common mucosal immunologic system involving the bronchus, breast and bowel. Adv Exp Med Biol (1978) 1.42
Galactoxylomannans of Cryptococcus neoformans. Infect Immun (1992) 1.42
Linkage of a gene for dominant non-syndromic deafness to chromosome 19. Hum Mol Genet (1995) 1.36
Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by 13C NMR spectroscopy. Carbohydr Res (1992) 1.34
Side group addition by xylosyltransferase and glucuronyltransferase in biosynthesis of capsular polysaccharide in Cryptococcus neoformans. J Med Vet Mycol (1990) 1.32
Characterization of protein and mannan polysaccharide antigens of yeasts, moulds, and actinomycetes. Curr Top Med Mycol (1985) 1.30
Soluble polysaccharides of Cryptococcus neoformans. Curr Top Med Mycol (1988) 1.29
Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect Immun (1997) 1.28
Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1997) 1.27
Changes in DNA polymerase activity associated with cell fusion in cultures of embryonic muscle. J Cell Physiol (1969) 1.26
Capsular polysaccharides of Clostridium perfringens Hobbs 5. Biochemistry (1971) 1.20
Composition of the capsular polysaccharides of Clostridium perfringens as a basis for their classification by chemotypes. Can J Microbiol (1975) 1.16
Use of mobile telephone short message service (SMS) as a reminder: the effect on patient attendance. Eur Arch Paediatr Dent (2009) 1.16
Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest (1990) 1.11
The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect Immun (1992) 1.11
Impact of specialised paediatric retrieval teams. Children are still transferred by non-specialist teams. BMJ (1996) 1.10
Enamel microabrasion: a microscopic evaluation of the "abrosion effect". Quintessence Int (1992) 1.10
Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect Immun (2001) 1.08
Immunochemistry of the capsular polysaccharides from Clostridium perfringens: selected Hobbs strains 1, 5, 9, and 10. Infect Immun (1972) 1.07
tctex-1: a candidate gene family for a mouse t complex sterility locus. Cell (1989) 1.07
Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy. Carbohydr Res (1996) 1.07
Early induction of interleukin-12 by human monocytes exposed to Cryptococcus neoformans mannoproteins. Infect Immun (2000) 1.06
Serotyping of Cryptococcus neoformans by dot enzyme assay. J Clin Microbiol (1996) 1.04
Clinical application of the Ottawa ankle rules for the use of radiography in acute ankle injuries: an independent site assessment. AJR Am J Roentgenol (1997) 1.02
Evaluation of a real-time hybrid three-dimensional echo and X-ray imaging system for guidance of cardiac catheterisation procedures. Med Image Comput Comput Assist Interv (2012) 1.01
Consanguineous nuclear families used to identify a new locus for recessive non-syndromic hearing loss on 14q. Hum Mol Genet (1995) 1.01
Glucuronoxylomannan of Cryptococcus neoformans serotype B: structural analysis by gas-liquid chromatography-mass spectrometry and 13C-nuclear magnetic resonance spectroscopy. Carbohydr Res (1991) 1.00
Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV-1 replication. Clin Exp Immunol (1997) 1.00
Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect Immun (1995) 0.99
Enzymatic assay for gentamicin. N Engl J Med (1973) 0.97
Studies of the decline of deoxyribonucleic acid polymerase activity during embryonic muscle cell fusion in vitro. Biochemistry (1970) 0.97
Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene. Infect Immun (1997) 0.97
An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan. Res Immunol (1990) 0.97
Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis. Ann Thorac Surg (1982) 0.96
T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A. Infect Immun (1993) 0.95
Structure of the 13C-enriched O-deacetylated glucuronoxylomannan of Cryptococcus neoformans serotype A determined by NMR spectroscopy. Carbohydr Res (1997) 0.95
Ultrastructure of acapsular mutant Cryptococcus neoformans cap 67 and monosaccharide composition of cell extracts. Mycopathologia (1986) 0.94
Structure and function studies of plant cell wall polysaccharides. Biochem Soc Trans (1994) 0.92
Constructed wetlands for environmental pollution control: a review of developments, research and practice in Ireland. Environ Int (2007) 0.92
Direct evidence for neutrino flavor transformation from neutral-current interactions in the Sudbury Neutrino Observatory. Phys Rev Lett (2002) 0.92
Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J Immunol (2001) 0.92
Risk of uterine rupture in Australian women attempting vaginal birth after one prior caesarean section: a retrospective population-based cohort study. BJOG (2010) 0.92
Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun (1993) 0.92
Immunochemical evidence for multiple serotypes of Bacteroides fragilis. J Clin Microbiol (1979) 0.92
Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia (1999) 0.90
Functional T cells in rabbits gut mucosal lymphocytes. Gut (1976) 0.90
The value of CT scans for children with headaches. Can J Neurol Sci (1990) 0.89
Exercise and pregnancy: a review. Birth (1994) 0.88
Capsular polysaccharide of Clostridium perfringens Hobbs 10. Infect Immun (1974) 0.88
Measurement of day and night neutrino energy spectra at SNO and constraints on neutrino mixing parameters. Phys Rev Lett (2002) 0.88
Structure of the capsular polysaccharide of Clostridium perfringens Hobbs 10 determined by NMR spectroscopy. Carbohydr Res (1997) 0.88
Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype C as determined by 2D 1H NMR spectroscopy. Carbohydr Res (1995) 0.88
Characterization of a cDNA encoding the 55 kDa B regulatory subunit of Arabidopsis protein phosphatase 2A. Plant Mol Biol (1995) 0.88
Cryptococcus neoformans and its cell wall components induce similar cytokine profiles in human peripheral blood mononuclear cells despite differences in structure. FEMS Immunol Med Microbiol (1999) 0.87
Health risk profile of prostitutes in Dublin. Int J STD AIDS (1998) 0.87
Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans. Mol Cell Probes (1989) 0.86
Capsular polysaccharide of Clostridium perfringens Hobbs 9. Infect Immun (1977) 0.86
Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J Neuroimmunol (2000) 0.86
Complete assignment of the 1H- and 13C-n.m.r. spectra of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans serotype B. Carbohydr Res (1991) 0.85
NG-Nitro-L-arginine protects against ischaemia-induced increases in nitric oxide and hippocampal neuro-degeneration in the gerbil. Eur J Pharmacol (1994) 0.85
Effectiveness of an abdominal obesity reduction programme in men: the GutBuster "waist loss' programme. Int J Obes Relat Metab Disord (1996) 0.85
Inotropic and calcium kinetic effects of calcium channel agonist and antagonist in isolated cardiac myocytes from cardiomyopathic hamsters. Circ Res (1990) 0.85
Giant intracranial aneurysms: diagnosis with special reference to computerised tomography. Clin Radiol (1980) 0.84
[Behavior modification related to health. I. Review of the theoretical literature]. Union Med Can (1980) 0.84
Structure of the capsular polysaccharide of Clostridium perfringens Hobbs 5 as determined by NMR spectroscopy. Carbohydr Res (1997) 0.84
Effect of lipid calories on weight gain, nitrogen balance, liver weight, and composition in total parenteral nutrition (TPN). Surg Forum (1977) 0.83
Metabolism in vitro and in vivo of pentazocine. Biochem Pharmacol (1969) 0.83
Evaluation of adjuvant postoperative radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (1982) 0.83
In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies. Infect Immun (1999) 0.82
Metabolic evaluation of nephrolithiasis in patients with medullary sponge kidney. JAMA (1981) 0.82
Ventricular activation during sympathetic imbalance and its computational reconstruction. J Appl Physiol (1985) (2001) 0.82
Immediate IgA precursor cells in rabbit intestinal lamina propria. Immunology (1978) 0.81
Trends, indications and outcomes of cardiac implantable device system extraction: a single UK centre experience over the last decade. Int J Clin Pract (2012) 0.81
A statistical model of catheter motion from interventional x-ray images: application to image-based gating. Phys Med Biol (2013) 0.81
Operational Definition of Active and Healthy Ageing (AHA): A Conceptual Framework. J Nutr Health Aging (2015) 0.80
Degenerative changes and detection of plasminogen in fetal membranes that rupture prematurely. Br J Obstet Gynaecol (1983) 0.80
HLA-DR-positive cells in the human amniochorion. Immunol Lett (1983) 0.80
Ventriculoperitoneal shunt malfunction due to migration of the abdominal catheter into the scrotum. J Pediatr Surg (1987) 0.80
Endoscopic findings in patients after definitive gastric surgery. Ir Med J (1975) 0.80
Familial infantile oesophageal achalasia. Arch Dis Child (1991) 0.80